417 related articles for article (PubMed ID: 19077931)
21. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
Plard C; Bressolle F; Fakhoury M; Zhang D; Yacouben K; Rieutord A; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2007 Sep; 60(4):609-20. PubMed ID: 17195068
[TBL] [Abstract][Full Text] [Related]
22. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
Wang YM; Sutow WW; Romsdahl MM; Perez C
Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
[TBL] [Abstract][Full Text] [Related]
23. Clonidine disposition in children; a population analysis.
Potts AL; Larsson P; Eksborg S; Warman G; Lönnqvist PA; Anderson BJ
Paediatr Anaesth; 2007 Oct; 17(10):924-33. PubMed ID: 17767627
[TBL] [Abstract][Full Text] [Related]
24. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.
Anderson BJ; Pons G; Autret-Leca E; Allegaert K; Boccard E
Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
26. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
27. Effective removal of methotrexate by high-flux hemodialysis.
Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
[TBL] [Abstract][Full Text] [Related]
28. [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy].
Miyauchi Y; Mii Y; Morishita T; Miura S; Honoki K; Aoki M; Kido A; Tamai S; Hino M; Nomura Y; Nakanishi E
Gan To Kagaku Ryoho; 1996 Apr; 23(5):595-9. PubMed ID: 8678518
[TBL] [Abstract][Full Text] [Related]
29. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Latz JE; Chaudhary A; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
[TBL] [Abstract][Full Text] [Related]
31. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
Debord J; Carpentier N; Sabot C; Bertin P; Marquet P; Treves R; Merle L; Lachâtre G
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
[TBL] [Abstract][Full Text] [Related]
32. ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis.
Kim IW; Yun HY; Choi B; Han N; Park SY; Lee ES; Oh JM
Clin Ther; 2012 Aug; 34(8):1816-26. PubMed ID: 22796246
[TBL] [Abstract][Full Text] [Related]
33. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
34. Influence of formulation on propofol pharmacokinetics and pharmacodynamics in anesthetized patients.
Calvo R; Telletxea S; Leal N; Aguilera L; Suarez E; De La Fuente L; Martin-Suarez A; Lukas JC
Acta Anaesthesiol Scand; 2004 Sep; 48(8):1038-48. PubMed ID: 15315624
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia.
Zhang C; Zhai S; Yang L; Wu H; Zhang J; Ke X
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):11-21. PubMed ID: 20040335
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.
Xuan D; Nicolau DP; Nightingale CH
Int J Antimicrob Agents; 2004 Mar; 23(3):291-5. PubMed ID: 15164971
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model].
Piekarczyk A; Zimak J; Taljański W
Med Wieku Rozwoj; 2000; 4(2 Suppl 2):27-33. PubMed ID: 11178326
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of ciprofloxacin in pediatric patients.
Rajagopalan P; Gastonguay MR
J Clin Pharmacol; 2003 Jul; 43(7):698-710. PubMed ID: 12856383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]